Insitro, a machine learning-powered drug discovery and development company, signed an early renewal for its 143,188-square-foot headquarters and R&D site at Alexandria Real Estate Equities’ Alexandria Center for Advanced Technologies – South San Francisco. The company has been an Alexandria tenant since 2018, when it signed up for 36,000 square feet at the campus.

Alexandria didn’t disclose the names of brokers involved in the deal. The Pasadena-based REIT entered the South San Francisco market in 1998 and has since grown a footprint of 3.4 million square feet there, including the one-million-square-foot Advanced Technologies campus at 279 E. Grand Ave.

Founded in 2018, Insitro secured a $400-million series C financing led by the Canada Pension Plan Investment Board in 2021, Fierce Biotech reported. Its early lease renewal is the second such deal signed by an Alexandria tenant in the past month, following Takeda Pharmaceutical’s recommitment to 222,925 square feet in Cambridge, MA.

Join 500+ owners, investors, developers, brokers, financiers and more at Connect Los Angeles 2024 on May 1 at the InterContinental Los Angeles Downtown. Register now to catch insights and forecasts on today’s CRE markets from SoCal and national industry leaders. 

Kyowa Kirin, a Japanese life sciences company, has selected Sanford, North Carolina, for its new pharmaceutical manufacturing complex. The $200 million investment will create more than 100 jobs. The company will utilize the Helix Innovation Park at the Brickyard, a new 895-acre industrial park in Lee County.

The Charlotte Business Journal reports the North Carolina Department of Commerce’s Economic Investment Committee approved roughly $2 million worth of incentives to lure the project. Earlier, the Sanford City Council and the Lee County Board of Commissioners approved an incentives package of $3.86 million and roughly $4.7 million, respectively.

Kyowa Kirin first entered the North American market when the U.S. Food and Drug Administration approved three medicines it markets in the United States. The company has three other manufacturing sites in North America.

Sanford, in recent years has landed large projects from Pfizer and Astellas Gene Therapies, part of Japanese firm Astellas Pharma.